CORRECTION Open Access



Correction to: A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety

Jie Mao^{1†}, Shujun Liu^{1†}, Min Ai^{2†}, Zhuo Wang³, Duowei Wang¹, Xianjing Li¹, Kaiyong Hu¹, Xinghua Gao^{1,4*} and Yong Yang^{1,4*}

Correction to: Journal of Hematology & Oncology (2017) 10:71 https://doi.org/10.1186/s13045-017-0442-y

The original article [1] contained an error in Fig. 1 which has since been corrected.

Author details

¹ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China. ²The Second Hospital of Nanjing, Nanjing 320100, China. ³School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China. ⁴Institute of Pharmaceutical Science, China Pharmaceutical University, No 639, Longmian Rd., Nanjing 211198, China.

Published online: 09 September 2022

Reference

 Mao J, et al. A novel melittin nano-liposome exerted excellent antihepatocellular carcinoma efficacy with better biological safety. J Hematol Oncol. 2017;10:71. https://doi.org/10.1186/s13045-017-0442-y.

The original article can be found online at https://doi.org/10.1186/s13045-017-0442-y.

Full list of author information is available at the end of the article



Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: 1620154324@cpu.edu.cn; valianty@hotmail.com

[†]Jie Mao, Shujun Liu and Min Ai have contributed equally to this work

¹ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China